Intellia Therapeutics, Inc.

NasdaqGM:NTLA Stock Report

Market Cap: US$1.2b

Intellia Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:NTLA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Oct 24SellUS$38,248Michael DubeIndividual2,012US$19.01
01 Jul 24SellUS$9,287Eliana ClarkIndividual405US$22.93
04 Mar 24SellUS$19,959Eliana ClarkIndividual605US$32.99
04 Mar 24SellUS$75,778James BastaIndividual2,297US$32.99
03 Jan 24SellUS$114,216Derek HicksIndividual3,877US$29.46
03 Jan 24SellUS$158,053Glenn GoddardIndividual5,365US$29.46
03 Jan 24SellUS$162,973Laura Sepp-LorenzinoIndividual5,532US$29.46
03 Jan 24SellUS$172,135David LebwohlIndividual5,843US$29.46
03 Jan 24SellUS$566,310John LeonardIndividual19,223US$29.46
03 Jan 24SellUS$112,095James BastaIndividual3,805US$29.46
03 Jan 24SellUS$135,954Eliana ClarkIndividual4,608US$30.12

Insider Trading Volume

Insider Buying: NTLA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of NTLA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,281,6441.26%
General Public5,894,5345.79%
Institutions94,672,39493%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.7%.

Top Shareholders

Top 25 shareholders own 73.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12%
ARK Investment Management LLC
12,255,440US$147.7m5.69%1.06%
9.6%
BlackRock, Inc.
9,772,742US$117.8m1.82%no data
9.45%
The Vanguard Group, Inc.
9,627,804US$116.0m5.8%no data
6.18%
Nikko Asset Management Co., Ltd.
6,297,796US$75.9m93.3%0.03%
5.05%
State Street Global Advisors, Inc.
5,143,534US$62.0m17.9%no data
4.86%
Deep Track Capital, LP
4,950,000US$59.6m3.13%1.9%
2.69%
Federated Hermes, Inc.
2,740,765US$33.0m19.1%0.08%
2.3%
Geode Capital Management, LLC
2,343,310US$28.2m2.15%no data
2.3%
FMR LLC
2,337,596US$28.2m4.93%no data
2.15%
AllianceBernstein L.P.
2,193,787US$26.4m23.1%0.01%
2.01%
Contrarius Investment Management Ltd.
2,047,218US$24.7m6.88%1.28%
1.96%
Casdin Capital, LLC
2,000,000US$24.1m0%1.57%
1.56%
Morgan Stanley, Investment Banking and Brokerage Investments
1,593,744US$19.2m-0.13%no data
1.42%
Dimensional Fund Advisors LP
1,447,250US$17.4m9.26%no data
1.37%
Pictet Asset Management Limited
1,394,911US$16.8m87.5%0.01%
1.06%
Himension Capital (Singapore) Pte Ltd
1,075,711US$13.0m4.44%0.92%
1.01%
Two Sigma Advisers, LP
1,027,617US$12.4m33.5%0.03%
0.97%
Citadel Advisors LLC
989,439US$11.9m29.7%0.01%
0.96%
Two Sigma Investments, LP
980,380US$11.8m18.2%0.03%
0.85%
Northern Trust Global Investments
866,290US$10.4m3.7%no data
0.82%
John Leonard
830,546US$10.0m0%no data
0.81%
Charles Schwab Investment Management, Inc.
827,545US$10.0m4.77%no data
0.8%
Chevy Chase Trust Company
811,033US$9.8m-22.2%0.03%
0.79%
Morgan Stanley Investment Management Inc.
809,480US$9.8m43.4%0.01%
0.74%
Balyasny Asset Management L.P.
749,861US$9.0m116%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 13:10
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intellia Therapeutics, Inc. is covered by 44 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jack AllenBaird
Huidong WangBarclays